FOLD Share Price Performance
US$14.34
5.48 (61.85%)
1.1% undervalued intrinsic discount
US$14.50
Fair Value
Price US$14.34
AnalystConsensusTarget US$14.50
AnalystHighTarget US$21.00
AnalystLowTarget US$9.00
Fair ValueUS$14.50
Share Pricen/a
Amicus Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 45 Fair Values set on narratives written by author
FOLD Community Narratives
AN
Fair Value US$14.5 1.1% undervalued intrinsic discount
FOLD: Key Patent Win Will Sustain Long-Term Product Exclusivity
0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
AN
Fair Value US$21 31.7% undervalued intrinsic discount
Gene Therapy Expansion Will Transform Rare Disease Therapeutics
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$9 59.3% overvalued intrinsic discount
Galafold Reliance Will Weigh On Margins While Cautious Progress Emerges
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
FOLD: Key Patent Win Will Sustain Long-Term Product Exclusivity
Key Takeaways Expanded patient identification and rapid international market uptake are driving broader revenue opportunities and supporting long-term operating leverage. Strong pipeline progress and disciplined expense management bolster prospects for sustainable profitability and future product diversification.Read more
205
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
AN
US$14.5
1.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
25.21%
Future PE
21.94x
Price in 2029
US$17.83
Gene Therapy Expansion Will Transform Rare Disease Therapeutics
Key Takeaways Amicus is set to outpace expectations with rapid global market expansion, driven by superior therapies, increased diagnoses, and best-in-class adherence rates. Strategic investments in supply chain, R&D, and partnerships position Amicus for lasting growth, strong margins, and durable leadership in rare disease therapeutics.Read more
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$21
31.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
35.01%
Future PE
23.58x
Price in 2028
US$25.92
Galafold Reliance Will Weigh On Margins While Cautious Progress Emerges
Key Takeaways Heavy reliance on a few key products and patent exclusivity increases vulnerability to competitive threats, regulatory shifts, and abrupt revenue declines. Policy scrutiny over pricing, rising R&D costs, and future pipeline risks may compress margins and limit sustainable earnings growth.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$9
59.3% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
16.56%
Future PE
23.67x
Price in 2028
US$10.99
Trending Discussion
Recently Updated Narratives
AN
FOLD: Acquisition Progress And Mixed BioMarin Outlook Will Shape Measured Risk Profile
Fair Value: US$14.5 1.1% undervalued intrinsic discount
27 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FOLD Galafold IP Outcomes Will Support Upside Repricing In This Undervalued Rare-Disease Name
Fair Value: US$21 31.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Galafold Reliance Will Weigh On Margins While Cautious Progress Emerges
Fair Value: US$9 59.3% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Amicus Therapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.086
- 88.50%
- -4.27%
- 143.2%
About FOLD
- Founded
- 2002
- Employees
- 511
- CEO
- WebsiteView website
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
